vs
IMAX（IMAX）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
IMAX的季度营收约是RIGEL PHARMACEUTICALS INC的1.8倍（$125.2M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 0.5%，领先383.5%），IMAX同比增速更快（35.1% vs 21.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 25.8%）
IMAX公司是加拿大的影视放映技术企业，1967年创立于蒙特利尔，总部位于多伦多地区，在纽约、洛杉矶均设有业务点。核心业务包括IMAX摄影机与放映系统的设计制造，同时面向全球合作影院提供影片开发、制作、后期及发行服务，是沉浸式观影技术领域的领先企业。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
IMAX vs RIGL — 直观对比
营收规模更大
IMAX
是对方的1.8倍
$69.8M
营收增速更快
IMAX
高出13.9%
21.2%
净利率更高
RIGL
高出383.5%
0.5%
两年增速更快
RIGL
近两年复合增速
25.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $125.2M | $69.8M |
| 净利润 | $637.0K | $268.1M |
| 毛利率 | 57.6% | 91.5% |
| 营业利润率 | 19.3% | 33.2% |
| 净利率 | 0.5% | 384.0% |
| 营收同比 | 35.1% | 21.2% |
| 净利润同比 | -88.0% | 1769.2% |
| 每股收益（稀释后） | $0.02 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IMAXRIGL
| Q4 25 | $125.2M | $69.8M | ||
| Q3 25 | $106.7M | $69.5M | ||
| Q2 25 | $91.7M | $101.7M | ||
| Q1 25 | $86.7M | $53.3M | ||
| Q4 24 | $92.7M | $57.6M | ||
| Q3 24 | $91.5M | $55.3M | ||
| Q2 24 | $89.0M | $36.8M | ||
| Q1 24 | $79.1M | $29.5M |
净利润IMAXRIGL
| Q4 25 | $637.0K | $268.1M | ||
| Q3 25 | $20.7M | $27.9M | ||
| Q2 25 | $11.3M | $59.6M | ||
| Q1 25 | $2.3M | $11.4M | ||
| Q4 24 | $5.3M | $14.3M | ||
| Q3 24 | $13.9M | $12.4M | ||
| Q2 24 | $3.6M | $-1.0M | ||
| Q1 24 | $3.3M | $-8.2M |
毛利率IMAXRIGL
| Q4 25 | 57.6% | 91.5% | ||
| Q3 25 | 63.1% | 93.2% | ||
| Q2 25 | 58.5% | 95.6% | ||
| Q1 25 | 61.4% | 91.7% | ||
| Q4 24 | 52.2% | 89.9% | ||
| Q3 24 | 55.8% | 85.5% | ||
| Q2 24 | 49.4% | 92.4% | ||
| Q1 24 | 59.3% | 93.1% |
营业利润率IMAXRIGL
| Q4 25 | 19.3% | 33.2% | ||
| Q3 25 | 27.2% | 40.9% | ||
| Q2 25 | 15.6% | 60.1% | ||
| Q1 25 | 19.3% | 23.9% | ||
| Q4 24 | 10.3% | 28.9% | ||
| Q3 24 | 21.2% | 25.4% | ||
| Q2 24 | 3.2% | 1.2% | ||
| Q1 24 | 15.3% | -23.6% |
净利率IMAXRIGL
| Q4 25 | 0.5% | 384.0% | ||
| Q3 25 | 19.4% | 40.2% | ||
| Q2 25 | 12.3% | 58.6% | ||
| Q1 25 | 2.7% | 21.5% | ||
| Q4 24 | 5.7% | 24.9% | ||
| Q3 24 | 15.2% | 22.5% | ||
| Q2 24 | 4.0% | -2.8% | ||
| Q1 24 | 4.1% | -27.9% |
每股收益（稀释后）IMAXRIGL
| Q4 25 | $0.02 | $14.11 | ||
| Q3 25 | $0.37 | $1.46 | ||
| Q2 25 | $0.20 | $3.28 | ||
| Q1 25 | $0.04 | $0.63 | ||
| Q4 24 | $0.09 | $0.82 | ||
| Q3 24 | $0.26 | $0.70 | ||
| Q2 24 | $0.07 | $-0.06 | ||
| Q1 24 | $0.06 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $151.2M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $337.9M | $391.5M |
| 总资产 | $894.0M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资IMAXRIGL
| Q4 25 | $151.2M | $155.0M | ||
| Q3 25 | $143.1M | $137.1M | ||
| Q2 25 | $109.3M | $108.4M | ||
| Q1 25 | $97.1M | $77.1M | ||
| Q4 24 | $100.6M | $77.3M | ||
| Q3 24 | $104.5M | $61.1M | ||
| Q2 24 | $91.6M | $49.1M | ||
| Q1 24 | $81.0M | $49.5M |
总债务IMAXRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益IMAXRIGL
| Q4 25 | $337.9M | $391.5M | ||
| Q3 25 | $349.5M | $117.6M | ||
| Q2 25 | $320.4M | $81.9M | ||
| Q1 25 | $299.5M | $18.6M | ||
| Q4 24 | $299.5M | $3.3M | ||
| Q3 24 | $289.4M | $-14.6M | ||
| Q2 24 | $267.2M | $-29.9M | ||
| Q1 24 | $258.8M | $-31.7M |
总资产IMAXRIGL
| Q4 25 | $894.0M | $513.6M | ||
| Q3 25 | $889.6M | $242.5M | ||
| Q2 25 | $868.6M | $206.7M | ||
| Q1 25 | $848.3M | $176.0M | ||
| Q4 24 | $830.4M | $164.0M | ||
| Q3 24 | $847.6M | $139.4M | ||
| Q2 24 | $827.4M | $128.4M | ||
| Q1 24 | $824.1M | $126.5M |
负债/权益比IMAXRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $29.4M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $28.0M | — |
| 自由现金流率自由现金流/营收 | 22.3% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 46.11× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $118.9M | — |
8季度趋势，按日历期对齐
经营现金流IMAXRIGL
| Q4 25 | $29.4M | $22.0M | ||
| Q3 25 | $67.5M | $24.0M | ||
| Q2 25 | $23.2M | $30.5M | ||
| Q1 25 | $7.0M | $-893.0K | ||
| Q4 24 | $11.5M | $14.5M | ||
| Q3 24 | $35.3M | $21.7M | ||
| Q2 24 | $35.0M | $302.0K | ||
| Q1 24 | $-11.0M | $-5.0M |
自由现金流IMAXRIGL
| Q4 25 | $28.0M | — | ||
| Q3 25 | $64.8M | — | ||
| Q2 25 | $20.9M | — | ||
| Q1 25 | $5.3M | — | ||
| Q4 24 | $6.9M | — | ||
| Q3 24 | $34.2M | — | ||
| Q2 24 | $33.5M | — | ||
| Q1 24 | $-12.1M | — |
自由现金流率IMAXRIGL
| Q4 25 | 22.3% | — | ||
| Q3 25 | 60.7% | — | ||
| Q2 25 | 22.8% | — | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | 7.4% | — | ||
| Q3 24 | 37.3% | — | ||
| Q2 24 | 37.6% | — | ||
| Q1 24 | -15.3% | — |
资本支出强度IMAXRIGL
| Q4 25 | 1.1% | — | ||
| Q3 25 | 2.6% | — | ||
| Q2 25 | 2.6% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 5.0% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 1.4% | — |
现金转化率IMAXRIGL
| Q4 25 | 46.11× | 0.08× | ||
| Q3 25 | 3.27× | 0.86× | ||
| Q2 25 | 2.06× | 0.51× | ||
| Q1 25 | 2.99× | -0.08× | ||
| Q4 24 | 2.16× | 1.01× | ||
| Q3 24 | 2.54× | 1.75× | ||
| Q2 24 | 9.78× | — | ||
| Q1 24 | -3.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
RIGL
暂无分部数据
